新闻中心

新闻中心

News Center
All Categories
Company News
Industry News

Current Opinion in Psychiatry Chinese Edition

Release Time

2022-06-21 16:35

   With the increasing number of mentally ill patients, words such as "depression", "anxiety" and "schizophrenia" began to appear frequently in the public eye. Although psychiatry has developed rapidly in China in recent years, and the diagnosis and treatment technology has become more and more mature, most doctors still have little understanding of the cutting-edge progress in the field of psychiatry.

   In this context, Shenzhen Foncoo Pharmaceutical Co., Ltd., in conjunction with "Window of Medicine" and "Wicko China", led by Professor Wang Gaohua, President of the Psychiatry Branch of the Chinese Medical Doctor Association, and more than 100 well-known experts in the spiritual field. With the strong support, the Chinese version of Current Opinion in Psychiatry (COP) was launched in April 2018, with a view to bringing more international academic frontier information to professionals in the field of psychiatry in my country and further promoting the academic development of the field of psychiatry in China.

 

 

     
 

DAVID J. KUPFER

Director of Psychiatry at the University of Pittsburgh

· Academician of the National Academy of Sciences

· Honorary Life Member of the American Psychiatric Association

· Chairman of the DSM-5 Program Committee

·Founder of the International Society for Bipolar Disorders

  

Norman Sartorius

· Past President of the World Psychiatric Association

· Former Director of the Department of Mental Health of the World Health Organization

  

Wang Gaohua

·President of the Chinese Medical Doctor Association Psychiatrist Branch

 

Previous page

Professor David J. Kupfer, Academician of the National Academy of Sciences: Writing and Publishing of High Impact Factor SCI Papers

Interview with Professor Jia Fujun

Next page

Previous page

Professor David J. Kupfer, Academician of the National Academy of Sciences: Writing and Publishing of High Impact Factor SCI Papers

Next page

Interview with Professor Jia Fujun

Related News

Foncoo Pharmaceutical participated in the 19th National Psychiatry Academic Conference of the Chinese Medical Association

Foncoo Pharmaceutical participated in the 19th National Psychiatry Academic Conference of the Chinese Medical Association

Sponsored by the Chinese Medical Association and the Psychiatry Branch of the Chinese Medical Association, and organized by the Chongqing Medical Association, the Psychiatry Branch of the Chongqing Medical Association, the First Affiliated Hospital of Chongqing Medical University, and the University City Hospital Affiliated to Chongqing Medical University The conference and the Academic Conference on Child and Adolescent Psychiatry were successfully held at Chongqing Yuelai International Conference Center from December 21 to 24, 2021.

2022-05-25

图片名称
2021-Foncoo Public Welfare

2021-Foncoo Public Welfare

On October 15, 2021, Foncoo Pharmaceutical donated 100,000 yuan in cash to the "Gu Xueqiu Pharmacy Education Fund" public welfare student aid project of the Beijing Renren Public Welfare Foundation-Shenyang Pharmaceutical University.

2022-05-25

图片名称
Foncoo Pharmaceutical's corporate culture 5.0 was officially released

Foncoo Pharmaceutical's corporate culture 5.0 was officially released

Official announcement! Seriously, don't be distracted!

2022-05-25

图片名称
Foncoo Pharmaceutical participated in the 16th National Academic Conference on Psychiatric Hospital Management

Foncoo Pharmaceutical participated in the 16th National Academic Conference on Psychiatric Hospital Management

On October 29-31, 2021, the 16th National Academic Conference on Psychiatric Hospital Management, hosted by the Chinese Hospital Association and the Chinese Hospital Association Psychiatric Hospital Branch, was held in Chongqing.

2022-05-25

图片名称

"Bupropion Hydrochloride Sustained-Release Tablets (II)" exclusively sold by Foncoo Pharmaceuticals was approved in China

Recently, "Bupropion Hydrochloride Sustained-Release Tablets (II) (150mg, 300mg)", exclusively sold by Pangu Pharmaceuticals (Mainland China), was approved by the State Drug Administration and deemed to have passed the consistency evaluation. The product, developed by Shanghai Xuantai Pharmaceuticals, was previously approved by the FDA in August 2017 and was marketed in the United States.

2022-05-25

图片名称
Foncoo Pharmaceutical participated in the 9th China Schizophrenia Forum

Foncoo Pharmaceutical participated in the 9th China Schizophrenia Forum

From October 22 to 24, 2021, the "Ninth China Schizophrenia Forum" was grandly held in Wuhan. The theme of this forum is "Infection, Inflammation and Schizophrenia".

2022-05-25

图片名称